Pegfilgrastim的全球市场：按产品、按应用、按给药途径、按分销管道、按地区

预计2024年全球Pegfilgrastim市场规模将达16.9亿美元，2024年至2031年复合年增长率为8.9%，2031年将达30.7亿美元。

图：2024 年Pegfilgrastim按地区分類的市场占有率(%)

Pegfilgrastim是非Filgrastim的长效形式，可刺激骨髓产生更多的白血球。Pegfilgrastim生物相似药是Pegfilgrastim的生技学名药或后续生技药品。Pegfilgrastim的生物相似药製剂在安全性、纯度或功效上不具临床意义的差异。生物相似药为创新生物製药提供了一种经济高效的替代品，并扩大了患者获得重要药物的机会。Pegfilgrastim生物相似药世界的成长是由对负担得起的治疗方案的需求不断增长和创新药物的专利到期推动的，导致多种生物仿製药进入市场。

市场动态：

全球Pegfilgrastim市场成长的驱动力是全球癌症发生率的上升。人们对生物相似药的认识不断提高以及政府对降低治疗成本的支持正在推动Pegfilgrastim生物相似药的采用。与参考生技药品相比，成本更低也推动了市场成长。然而，生物相似药的核准存在严格的规定，这可能给市场参与企业带来挑战。授予参考药物的资料独占权也减缓了生物相似药的市场进入。此外，复杂的製造流程和对专业知识的需求可能会阻碍市场成长。各种核准的生物相似药和新兴市场的强大管道的存在可以为市场成长提供机会。

本研究的主要特点

本报告提供了全球Pegfilgrastim市场的详细分析，包括市场规模（十亿美元）和年复合成长率（CAGR%）。

它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。

根据公司亮点、产品系列、主要亮点、绩效和策略等参数，包括全球Pegfilgrastim市场主要公司的概况。

主要企业包括 Amgen、AryoGen Pharmed、Coherus Biosciences、Mylan、Dr Reddy's Laboratories 和 Biocon。

本报告中的见解将帮助负责人和公司经营团队就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。

Pegfilgrastim全球市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、分销商、新进业者和财务分析师。

相关人员可以透过分析全球Pegfilgrastim市场时所使用的各种策略矩阵来促进决策。

目录

第一章 研究目的与前提

• 研究目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要

第三章 市场动态、法规与趋势分析

• 市场动态
  • 促进因素
  • 抑制因素
  • 机会
• 影响分析
• 市场趋势
• 主要进展
• 监管场景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

第四章全球Pegfilgrastim生物相似药市场 – COVID-19 的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第 5 章 全球Pegfilgrastim市场（按产品），2019-2031 年（十亿美元）

• Pegfilgrastim生物类似药
• Pegfilgrastim标准品

第六章 全球Pegfilgrastim市场，依应用分类，2019-2031 年（十亿美元）

• 肿瘤学
• 慢性嗜中性白血球低下症
• 干细胞移植
• 其他的

第 7 章 全球Pegfilgrastim市场，依给药途径，2019-2031 年（十亿美元）

• 皮下注射
• 静脉
• 墨水匣

第 8 章 全球Pegfilgrastim市场，依通路划分，2019-2031 年（十亿美元）

• 医院药房
• 零售药房
• 网路药房

第9章2019-2031年全球Pegfilgrastim市场（按地区）（十亿美元）

• 拉丁美洲
• 欧洲
• 亚太地区
• 中东

第10章竞争格局

• 公司简介
  • CoherusBioSciences
  • Mylan NV
  • Biocon
  • Sandoz（a Novartis division）
  • Pfizer Inc.
  • Apotex Inc.
  • Cinfa Biotech
  • Gedeon Richter
  • StadaArzneimittel AG
  • Mundipharma
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Intas Pharmaceuticals
  • Biocad
  • Genor Biopharma
  • Qilu Pharmaceutical
  • Henlius Biotech

第十一章分析师建议

• 命运之轮
• 分析师观点
• 一致的机会图

第十二章调查方法

• 参考
• 调查方法

Global pegfilgrastim biosimilars market is estimated to be valued at USD 1.69 Bn in 2024 and is expected to reach USD 3.07 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031.

Figure. Pegfilgrastim Biosimilars Market Share (%), By Region 2024

Pegfilgrastim is a long-acting form of filgrastim that stimulates the bone marrow to produce more white blood cells. Pegfilgrastim biosimilars are follow-on biologics or subsequent entry biologics of pegfilgrastim. These biosimilars have no clinically meaningful differences in terms of safety, purity, and potency from the original version of pegfilgrastim, when administered at the same dose. Biosimilars provide a cost-effective alternative to innovative biologics and expand access to important medicines for patients. Global pegfilgrastim biosimilars growth is driven by increasing demand for affordable treatment options and the patent expiration of innovator drugs, thus, leading to market entry of multiple biosimilars.

Market Dynamics:

Global pegfilgrastim biosimilars market growth is driven rising prevalence of cancer cases globally. Growing awareness about biosimilar drugs and government thrust on increasing affordability of treatment have boosted adoption of pegfilgrastim biosimilars. Lower costs compared to reference biologics also drives the market growth. However, presence of stringent regulations for biosimilar approval can pose challenge for market players. Data exclusivity granted to reference drugs also delays market entry of biosimilars. Furthermore, complex production processes and the need for specialized expertise can hamper the market growth. Presence of strong pipeline with various biosimilar approvals and emerging markets can offer opportunities for market growth.

Key features of the study

This report provides in-depth analysis of the global pegfilgrastim biosimilars market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global pegfilgrastim biosimilars market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Amgen, AryoGen Pharmed, Coherus Biosciences, Mylan, Dr Reddy's Laboratories, and Biocon

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global pegfilgrastim biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pegfilgrastim biosimilars market

Detailed Segmentation-

• By Product
  • Pegfilgrastim Biosimilars
  • Pegfilgrastim Reference Product
• By Application
  • Oncology
  • Chronic Neutropenia
  • Stem Cell Transplantation
  • Others
• By Route of Administration
  • Subcutaneous
  • Intravenous
• By Distribution Channel
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • CoherusBioSciences
  • Mylan N.V.
  • Biocon
  • Sandoz (a Novartis division)
  • Pfizer Inc.
  • Apotex Inc.
  • Cinfa Biotech
  • Gedeon Richter
  • StadaArzneimittel AG
  • Mundipharma
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals
  • Reddy's Laboratories
  • Intas Pharmaceuticals
  • Biocad
  • Genor Biopharma
  • Qilu Pharmaceutical
  • Henlius Biotech

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product
  • Market Snapshot, By Application
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Pegfilgrastim Biosimilars Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Pegfilgrastim Biosimilars Market, By Product, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Pegfilgrastim Biosimilars
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Pegfilgrastim Reference Product
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Pegfilgrastim Biosimilars Market, By Application, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oncology
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Chronic Neutropenia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Stem Cell Transplantation
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Pegfilgrastim Biosimilars Market, By Route of Administration, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Subcutaneous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Intravenous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Cartridge
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Pegfilgrastim Biosimilars Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Pegfilgrastim Biosimilars Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • CoherusBioSciences
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mylan N.V.
  • Biocon
  • Sandoz (a Novartis division)
  • Pfizer Inc.
  • Apotex Inc.
  • Cinfa Biotech
  • Gedeon Richter
  • StadaArzneimittel AG
  • Mundipharma
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Intas Pharmaceuticals
  • Biocad
  • Genor Biopharma
  • Qilu Pharmaceutical
  • Henlius Biotech

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. Research Methodology

• References
• Research Methodology
• About us and Sales Contact